Lucy Therapeutics develops novel mitochondrial small-molecule therapies and diagnostic biomarkers for complex neurological diseases including Alzheimer’s, Parkinson’s and Rett syndrome. Its platform analyzes mitochondrial, environmental and genetic drivers simultaneously to create a detailed knowledge map that uncovers shared biological pathways and unique drug targets. The company has built the team, assays and translational tools to advance two drug development projects from idea to in vivo proof-of-concept in key animal models within three years. LucyTx has identified lead compound series for its Rett syndrome and Parkinson’s programs, defined translational target engagement, and identified disease biomarkers. The company plans Investigational New Drug (IND) filings in early 2025. LucyTx has raised more than $36 million to date, including a recent $12.5 million financing. Lucy Therapeutics develops small‑molecule drugs that target mitochondrial biology to treat central nervous system diseases and has also developed a peripheral mitochondrial biomarker. Its platform has produced compounds currently in advanced lead optimization and is moving toward preclinical candidate nomination for Parkinson’s disease and Rett syndrome. The company emphasizes targeting “disease‑bottleneck” steps in cellular bioenergetics rather than strictly genetically implicated targets. Recent work links mitochondrial and metabolic processes to epigenetic and chromatin modulation, which LucyTx uses to identify selective interventions in diseased versus healthy cells. The team plans to use new funding to generate supporting efficacy, toxicology, and biomarker data to advance its Parkinson’s program and to identify additional targets that modulate rate‑limiting steps of pathology. LucyTx also gains access to MJFF’s network of advisors and external partners as part of the award. Financially, LucyTx disclosed a $4.9M grant from the Michael J. Fox Foundation and previously raised a $4M seed round led by The Engine and Safar Partners; it has also received support from the Massachusetts Life Science Center and Golden Tickets from Biogen and Bristol Myers‑Squibb.

Total raised

$17M

Funding rounds

3

Latest round

Equity

Latest activity

May 2024